Case of Imatinib Susceptibility to CYP3A4-Mediated Drug-Drug Interactions in a Patient With Gastrointestinal Stromal Tumor

Am J Ther. 2024 Jan-Feb;31(1):e66-e69. doi: 10.1097/MJT.0000000000001535. Epub 2022 Jul 15.

Authors

Tatsuhiro Fujimiya¹, Hideki Sugita^{1

2}, Masaoki Kin², Haruki Funakoshi^{1

2}, Yutaro Kubota³, Takuya Tsunoda³

Affiliations

¹ Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan.
² Department of Pharmacy, Showa University Hospital, Tokyo, Japan.
³ Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.

PMID: 35792063
DOI: 10.1097/MJT.0000000000001535

No abstract available

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Cytochrome P-450 CYP3A / therapeutic use
Drug Interactions
Gastrointestinal Neoplasms* / drug therapy
Gastrointestinal Neoplasms* / pathology
Gastrointestinal Stromal Tumors* / drug therapy
Gastrointestinal Stromal Tumors* / pathology
Humans
Imatinib Mesylate / therapeutic use

Substances

Imatinib Mesylate
Cytochrome P-450 CYP3A
Antineoplastic Agents
CYP3A4 protein, human